Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.64 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.64 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.62 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761014 | 0.89 | OPRL1 (0.64) | HSD17B10OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL21634299 | 0.89 | HSD17B10 (0.62) | HSD17B10OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL9998386 | 0.88 | OPRM1 (0.60) | OPRM1OPRK1OPRL1OPRD1SLC6A9 | |
| SCHEMBL21634315 | 0.88 | HSD17B10 (0.60) | HSD17B10OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL5329597 | 0.87 | OPRM1 (0.62) | HSD17B10OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL13853705 | 0.85 | OPRK1 (0.58) | HSD17B10OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL14543210 | 0.85 | HSD17B10 (0.60) | HSD17B10OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL21688404 | 0.84 | OPRK1 (0.57) | HSD17B10OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL5459394 | 0.84 | OPRM1 (0.57) | HSD17B10OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL4049661 | 0.83 | OPRK1 (0.47) | HSD17B10OPRM1OPRK1OPRL1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032535-B1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | claimed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | claimed |
| EP-2032535-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | Sanofi-Aventis (FR) | 2009-03-11 | — | — | EP | claimed |
| WO-2007137738-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-12-06 | — | — | WO | claimed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | claimed |
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-3317279-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-05-09 | — | — | EP | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2520568-A1 | Spirocyclic nitriles as inhibitors of protease | SANOFI (FR) | 2012-11-07 | — | — | EP | disclosed |
| EP-2032535-B1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| WO-2011160084-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | HSD17B10 2768/4885OPRM1 4280/4885OPRK1 3749/4885 |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | HSD17B10 2768/4885OPRM1 4280/4885OPRK1 3749/4885 |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | HSD17B10 2768/4885OPRM1 4280/4885OPRK1 3749/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | HSD17B10 3531/4885OPRM1 3240/4885OPRK1 2729/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | HSD17B10 2768/4885OPRM1 4280/4885OPRK1 3749/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | HSD17B10 1611/4885OPRM1 92/4885OPRK1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.